Certain applications requires a scalable cost effective storage and execution system with facility to store data and have feature to analyze data to its finest granularity level in future. This ...increase the quality and accuracy of result analysis. Wireless sensor Network (WSN) nodes deployed for certain data intensive applications such as surveillance, war zone monitoring etc. generates a massive amount of raw data. There is an essential requirement of storing this data in its native format for analytics purpose in anticipation of future requirements. In present work, a data lake implemented on Amazon AWS is presented for storage of data in original version for future reference. Data Lake implementation service is utilized for storing the data generated in big volumes, high speed and in variety. The data in Data Lake is stored in three zones i.e. raw, reformed and curated. This paper proposes an efficient method of storing structured, unstructured and semi-structured, data in to Data Lake for future retrieval and analytics purpose. The results are comprehensively presented highlighting the advantages of using Data Lake in place of data warehouses.
Statins and aspirin have been proposed for treatment of COVID-19 because of their anti-inflammatory and anti-thrombotic properties. Several observational studies have shown favourable results. There ...is a need for a randomised controlled trial. In this single-center, open-label, randomised controlled trial, 900 RT-PCR positive COVID-19 patients requiring hospitalisation, were randomly assigned to receive either atorvastatin 40 mg (Group A, n = 224), aspirin 75 mg (Group B, n = 225), or both (Group C, n = 225) in addition to standard of care for 10 days or until discharge whichever was earlier or only standard of care (Group D, n = 226). The primary outcome variable was clinical deterioration to WHO Ordinal Scale for Clinical Improvement greater than or equai to 6. The secondary outcome was change in serum C-reactive protein, interleukin-6, and troponin I. The primary outcome occurred in 25 (2.8%) patients: 7 (3.2%) in Group A, 3 (1.4%) in Group B, 8 (3.6%) in Group C, and 7 (3.2%) in Group D. There was no difference in primary outcome across the study groups (P = 0.463). Comparison of all patients who received atorvastatin or aspirin with the control group (Group D) also did not show any benefit Atorvastatin: HR 1.0 (95% CI 0.41-2.46) P = 0.99; Aspirin: HR 0.7 (95% CI 0.27-1.81) P = 0.46. The secondary outcomes revealed lower serum interleukin-6 levels among patients in Groups B and C. There was no excess of adverse events. Among patients admitted with mild to moderate COVID-19 infection, additional treatment with aspirin, atorvastatin, or a combination of the two does not prevent clinical deterioration.
Full text
Available for:
DOBA, IZUM, KILJ, NUK, PILJ, PNG, SAZU, SIK, UILJ, UKNU, UL, UM, UPUK
26.
ENTREPRENEURSHIP AND COVID-19 Shinghal, Kshitij; Saxena, Amit
International Journal of Scientific Research and Management Studies,
05/2020, Volume:
4, Issue:
4
Journal Article
DEVELOPING ENTREPRENEURIAL MINDSET IN ENGINEERS Shinghal, Kshitij; Saxena, Amit
International Journal of Scientific Research and Management Studies,
09/2017, Volume:
4, Issue:
2
Journal Article
PDF
